Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)‘s stock had its “buy” rating reaffirmed by investment analysts at Piper Jaffray Companies in a research note issued to investors on Tuesday. They presently have a $36.00 target price on the biotechnology company’s stock. Piper Jaffray Companies’ price target would indicate a potential upside of 350.00% from the stock’s current price.

EIGR has been the subject of several other research reports. Zacks Investment Research upgraded shares of Eiger BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research note on Tuesday, June 6th. BTIG Research assumed coverage on shares of Eiger BioPharmaceuticals in a research note on Friday, July 14th. They issued a “buy” rating and a $32.00 price objective for the company. Oppenheimer Holdings, Inc. set a $34.00 price objective on shares of Eiger BioPharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 8th. Wedbush reiterated an “ourperform” rating and issued a $34.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Monday. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $27.00 price objective (down previously from $28.00) on shares of Eiger BioPharmaceuticals in a research note on Monday, May 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $28.46.

Eiger BioPharmaceuticals (NASDAQ:EIGR) opened at 8.00 on Tuesday. The firm’s market cap is $66.94 million. The company’s 50-day moving average is $8.34 and its 200 day moving average is $9.01. Eiger BioPharmaceuticals has a one year low of $6.10 and a one year high of $17.98.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings data on Friday, May 12th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.35) by $0.01. Equities analysts anticipate that Eiger BioPharmaceuticals will post ($5.40) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Eiger BioPharmaceuticals’ (NASDAQ:EIGR) Buy Rating Reaffirmed at Piper Jaffray Companies” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/eiger-biopharmaceuticals-nasdaqeigr-buy-rating-reaffirmed-at-piper-jaffray-companies/1488981.html.

Hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter worth approximately $272,000. Hikari Power Ltd raised its stake in shares of Eiger BioPharmaceuticals by 491.0% in the second quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock worth $482,000 after buying an additional 50,672 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Eiger BioPharmaceuticals by 6.4% in the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after buying an additional 871 shares during the period. Finally, LMR Partners LLP acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter worth approximately $116,000. Institutional investors and hedge funds own 69.04% of the company’s stock.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.